Pyxis Oncology (PYXS) EPS (Weighted Average and Diluted) (2021 - 2025)
Pyxis Oncology (PYXS) reported EPS (Weighted Average and Diluted) of -$0.29 for Q4 2025, up 50.85% year-over-year from -$0.19 in Q4 2024, and up 17.14% quarter-over-quarter from -$0.35 in Q3 2025.
Pyxis Oncology (PYXS) EPS (Weighted Average and Diluted) (2021 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.29 in Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$0.29, up 50.85% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.29 (changed 0.0% YoY), and the FY2025 annual result was -$1.28, up 3.03% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.29 in Q4 2025 per PYXS's latest filing, from -$0.35 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $31.32 in Q4 2021 and troughed at -$8.96 in Q3 2021.
- A 5-year average of $0.46 and a median of -$0.41 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) jumped 90.51% in 2022, then plunged 483.33% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $31.32 in 2021, then slumped by 103.32% to -$1.04 in 2022, then soared by 68.27% to -$0.33 in 2023, then plunged by 78.79% to -$0.59 in 2024, then surged by 50.85% to -$0.29 in 2025.
- Business Quant data shows PYXS's EPS (Weighted Average and Diluted) at -$0.29 in Q4 2025, -$0.35 in Q3 2025, and -$0.3 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.29 |
| Sep 30, 2025 | -0.35 |
| Jun 30, 2025 | -0.30 |
| Mar 31, 2025 | -0.35 |
| Dec 31, 2024 | -0.59 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.06 |
| Dec 31, 2023 | -0.33 |
| Sep 30, 2023 | -0.56 |
| Jun 30, 2023 | -0.41 |
| Mar 31, 2023 | -0.54 |
| Dec 31, 2022 | -1.04 |
| Sep 30, 2022 | -0.85 |
| Jun 30, 2022 | -0.79 |
| Mar 31, 2022 | -0.97 |
| Dec 31, 2021 | 31.32 |
| Sep 30, 2021 | -8.96 |
| Jun 30, 2021 | -5.54 |